Agile Therapeutics Receives a Buy from FBR Capital

By Carrie Williams

FBR Capital analyst Edward White reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX) yesterday and set a price target of $16. The company’s shares opened today at $7.64.

White wrote:

“After the market close on November 7, Agile Therapeutics announced above- consensus 3Q16 earnings results. Although Agile did not host a call, we had an opportunity to speak with management to discuss the pipeline, the SECURE study, and its financial position. We believe the Agile story continues to be positive, with data from the Phase III SECURE trial expected in January 2017. The last patient visit in the SECURE trial has been completed with data verification and database lock to be completed by year-end 2016. We believe Twirla could potentially be approved by the FDA in 2H17, so—assuming approval—we anticipate a launch in early 2018. We continue to believe investors should become involved in the stock prior to the release of data, as we think the stock could run up into the data release.”

According to, White is ranked 0 out of 5 stars with an average return of -12.8% and a 19.3% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, RXi Pharmaceuticals Corp, and Synthetic Biologics Inc.

Agile Therapeutics has an analyst consensus of Moderate Buy.

The company has a one year high of $10.41 and a one year low of $5.32. Currently, Agile Therapeutics has an average volume of 53.06K.

Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company, which focused on the development and commercialization of new prescription contraceptive products. Its product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company products include Twirla AG200, AG200-ER and AG200-SP. Agile Therapeutics was founded on December 22, 1997 and is headquartered in Princeton, NJ.